Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting

Stock Information for Cellectis S.A.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cellectis S.A.

Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update
Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025
Cellectis Presents 'Smart CAR T' Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025
Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial Officer
Cellectis announces the drawdown of the third tranche of Euro5 million under the credit facility agreement entered with the European Investment Bank (EIB)
Cellectis Provides Business Updates and Financial Results for Third Quarter 2024
Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024
Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.